Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Furue

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]N Nukariya, H Niitani, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1992
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]M Suminaga, H Furue, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1992
[A phase I study of DWA2114R]Y Ariyoshi, A Wakui, K Hasegawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1991
[Evaluation of cardiotoxicity in new anthracycline analog ME 2303. ME 2303 Study Group]K Okuma, Y Ariyoshi, A Wakui, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 1, 1983
[Phase II clinical trial of MCNU]H Furue, M Kako, H Mugitani, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 8, 1998
[Phase I study of orally administered UFT plus l-leucovorin]N Horikoshi, K Aiba, R Kanamaru, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1982
[Phase I study of a new anticancer agent CAM--results of cooperative study]T Saito, I Nakao, A Wakui, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1983
[Pancreatic oncofetal antigen (POA)]H Mugitani, H Furue, M Kako, et al.
International Journal of Hematology|October 1, 1996
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study GroupY Kagami, Y Ariyoshi, A Horiuchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 1, 1997
[Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]N Yoshiya, S Kodama, Y Aoki, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]N Nukariya, H Niitani, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1992
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]M Suminaga, H Furue, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1992
[A phase I study of DWA2114R]Y Ariyoshi, A Wakui, K Hasegawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1991
[Evaluation of cardiotoxicity in new anthracycline analog ME 2303. ME 2303 Study Group]K Okuma, Y Ariyoshi, A Wakui, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 1, 1983
[Phase II clinical trial of MCNU]H Furue, M Kako, H Mugitani, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 8, 1998
[Phase I study of orally administered UFT plus l-leucovorin]N Horikoshi, K Aiba, R Kanamaru, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1982
[Phase I study of a new anticancer agent CAM--results of cooperative study]T Saito, I Nakao, A Wakui, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1983
[Pancreatic oncofetal antigen (POA)]H Mugitani, H Furue, M Kako, et al.
International Journal of Hematology|October 1, 1996
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study GroupY Kagami, Y Ariyoshi, A Horiuchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 1, 1997
[Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]N Yoshiya, S Kodama, Y Aoki, et al.
Pageof 15